-
Something wrong with this record ?
Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity
L. Zatloukalová, T. Filipský, P. Mladěnka, V. Semecký, K. Macáková, M. Holečková, J. Vávrová, V. Palicka, R. Hrdina,
Language English Country Canada
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
22439652
DOI
10.1139/y2012-009
Knihovny.cz E-resources
- MeSH
- Iron Chelating Agents pharmacology MeSH
- Hemodynamics drug effects MeSH
- Myocardial Infarction chemically induced drug therapy MeSH
- Isoproterenol antagonists & inhibitors MeSH
- Cardiotonic Agents pharmacology therapeutic use MeSH
- Rats MeSH
- Disease Models, Animal MeSH
- Myocardium metabolism pathology MeSH
- Rats, Wistar MeSH
- Razoxane pharmacology therapeutic use MeSH
- Calcium metabolism MeSH
- Iron metabolism MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Positive effects of dexrazoxane (DEX) in anthracycline cardiotoxicity have been mostly assumed to be associated with its iron-chelating properties. However, this explanation has been recently questioned. Iron plays also an important role in the catecholamine cardiotoxicity. Hence in this study, the influence of DEX on a catecholamine model of acute myocardial infarction (100 mg/kg of isoprenaline by subcutaneous injection) was assessed: (i) the effects of an intravenous dose of 20.4 mg/kg were analyzed after 24 h, (ii) the effects were monitored continuously during the first two hours after drug(s) administration to examine the mechanism(s) of cardioprotection. Additional in vitro experiments on iron chelation/reduction and influence on the Fenton chemistry were performed both with isoprenaline/DEX separately and in their combination. DEX partly decreased the mortality, reduced myocardial calcium overload, histological impairment, and peripheral haemodynamic disturbances 24 h after isoprenaline administration. Continuous 2 h experiments showed that DEX did not influence isoprenaline induced atrioventricular blocks and had little effect on the measured haemodynamic parameters. Its protective effects are probably mediated by inhibition of late myocardial impairment and ventricular fibrillation likely due to inhibition of myocardial calcium overload. Complementary in vitro experiments suggested that iron chelation properties of DEX apparently did not play the major role.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12034641
- 003
- CZ-PrNML
- 005
- 20121206123048.0
- 007
- ta
- 008
- 121023s2012 xxc f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1139/y2012-009 $2 doi
- 035 __
- $a (PubMed)22439652
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxc
- 100 1_
- $a Zatloukalová, Libuše $u Charles University in Prague, Department of Pharmacology and Toxicology, Heyrovského, Hradec Králové, Czech Republic.
- 245 10
- $a Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity / $c L. Zatloukalová, T. Filipský, P. Mladěnka, V. Semecký, K. Macáková, M. Holečková, J. Vávrová, V. Palicka, R. Hrdina,
- 520 9_
- $a Positive effects of dexrazoxane (DEX) in anthracycline cardiotoxicity have been mostly assumed to be associated with its iron-chelating properties. However, this explanation has been recently questioned. Iron plays also an important role in the catecholamine cardiotoxicity. Hence in this study, the influence of DEX on a catecholamine model of acute myocardial infarction (100 mg/kg of isoprenaline by subcutaneous injection) was assessed: (i) the effects of an intravenous dose of 20.4 mg/kg were analyzed after 24 h, (ii) the effects were monitored continuously during the first two hours after drug(s) administration to examine the mechanism(s) of cardioprotection. Additional in vitro experiments on iron chelation/reduction and influence on the Fenton chemistry were performed both with isoprenaline/DEX separately and in their combination. DEX partly decreased the mortality, reduced myocardial calcium overload, histological impairment, and peripheral haemodynamic disturbances 24 h after isoprenaline administration. Continuous 2 h experiments showed that DEX did not influence isoprenaline induced atrioventricular blocks and had little effect on the measured haemodynamic parameters. Its protective effects are probably mediated by inhibition of late myocardial impairment and ventricular fibrillation likely due to inhibition of myocardial calcium overload. Complementary in vitro experiments suggested that iron chelation properties of DEX apparently did not play the major role.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a vápník $x metabolismus $7 D002118
- 650 _2
- $a kardiotonika $x farmakologie $x terapeutické užití $7 D002316
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a hemodynamika $x účinky léků $7 D006439
- 650 _2
- $a železo $x metabolismus $7 D007501
- 650 _2
- $a chelátory železa $x farmakologie $7 D007502
- 650 _2
- $a isoprenalin $x antagonisté a inhibitory $7 D007545
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a infarkt myokardu $x chemicky indukované $x farmakoterapie $7 D009203
- 650 _2
- $a myokard $x metabolismus $x patologie $7 D009206
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 650 _2
- $a razoxan $x farmakologie $x terapeutické užití $7 D011929
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Filipský, Tomáš
- 700 1_
- $a Mladěnka, Přemysl
- 700 1_
- $a Semecký, Vladimír
- 700 1_
- $a Macáková, Kateřina
- 700 1_
- $a Holečková, Magdalena
- 700 1_
- $a Vávrová, Jaroslava
- 700 1_
- $a Palicka, Vladimir
- 700 1_
- $a Hrdina, Radomír
- 773 0_
- $w MED00001020 $t Canadian journal of physiology and pharmacology $x 1205-7541 $g Roč. 90, č. 4 (2012), s. 473-84
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22439652 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a
- 990 __
- $a 20121023 $b ABA008
- 991 __
- $a 20121206123121 $b ABA008
- 999 __
- $a ok $b bmc $g 956651 $s 792138
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 90 $c 4 $d 473-84 $i 1205-7541 $m Canadian journal of physiology and pharmacology $n Can J Physiol Pharmacol $x MED00001020
- LZP __
- $a Pubmed-20121023